All News

Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

FDA action date set for July 26, 2025.

Your daily dose of the clinical news you may have missed.

Peter McAllister, MD,

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.

Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

Your daily dose of the clinical news you may have missed.

Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.

JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

The study will assess the safety, tolerability, and pharmacokinetics of PMN310 in individuals with mild cognitive impairment or early-stage AD.

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.